Mankind Pharma's 35th AGM: All Resolutions Approved with Requisite Majority
Mankind Pharma's 35th AGM on August 4, 2026, successfully passed all four resolutions. Key approvals included financial statement adoption and director re-appointments for Mr. Rajeev Juneja and Mr. Satish Kumar Sharma. Cost auditor remuneration for FY27 was also ratified.
The approval of financial statements and director re-appointments are routine corporate governance activities. While positive, they do not represent a significant shift in the company's strategic direction or financial outlook.
All resolutions presented at the AGM were approved with the requisite majority, indicating shareholder confidence and support for the company's decisions.
Mankind Pharma Limited held its 35th Annual General Meeting (AGM) on Tuesday, August 4, 2026, through video conferencing. The meeting, which commenced at 3:30 p.m. IST and concluded at 4:56 p.m. IST, saw all four resolutions presented being approved by the shareholders with the required majority.
The resolutions included the adoption of standalone and consolidated audited financial statements for the financial year ended March 31, 2026. Additionally, the re-appointment of Mr. Rajeev Juneja as a Director, the re-appointment of Mr. Satish Kumar Sharma as Whole-time Director, and the ratification of the remuneration of cost auditors for the Financial Year 2026-27 were also approved.
The voting results, compiled by Scrutinizer Mohit Chaurasia of Mohit Chaurasia & Associates, indicated strong support for all agenda items. The voting process, which included remote e-voting and e-voting during the AGM, was conducted via CDSL's platform. The record date for determining voting eligibility was July 29, 2026, with 166,703 shareholders on record.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.